Investigation into the mechanism of action of PEDF in the resistant cells indicated that the anti-tumor activity of PEDF in vivo was due, in part, to its ability to inhibit angiogenesis, as was demonstrated by a reduction in microvessel density and an increase in apoptosis. This evidence concerns the gene SERPINF1 and neoplasm.